Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States

PURPOSE: Recently, the DESTINY-Breast04 trial revealed that significant benefits in both overall survival (OS) and progression-free survival (PFS) in patients with HER2-low advanced or metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd) compared with chemotherapy. The current study...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Yitian, Wu, Bin, Liu, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747849/
https://www.ncbi.nlm.nih.gov/pubmed/36532255
http://dx.doi.org/10.2147/BCTT.S389696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747849/
https://www.ncbi.nlm.nih.gov/pubmed/36532255
http://dx.doi.org/10.2147/BCTT.S389696

Ejemplares similares